No description available.

A nanoemulsão LDE tem composição lipídica semelhante à da LDL natural e é utilizada para estudos do metabolismo da LDL. Estudos anteriores mostraram que a LDE é captada pelas células pelo LDL-r, porém outros receptores podem estar envolvidos nesta captação, como LRP-1, CD36 e CD68. Os objetivos deste estudo foram: investigar a captação da LDE por células endoteliais, fibroblastos, monócitos, macrófagos e H292, identificar os receptores envolvidos na captação da LDE pelas mesmas células e avaliar os efeitos da modificação química da LDE sobre a estabilidade, captação celular, lipoperoxidação celular e citotoxicidade. A LDE marcada com [3H]-colesterol livre e [14C]-éster de colesterol foi incubada por 4 horas com as linhagens celulares. Após a incubação, foram realizados os testes de captação da LDE e competição da LDE com a LDL natural. A expressão dos receptores LDL-r, LRP, CD36 e CD68 foi avaliada pelos métodos de imunocitoquímica, citometria de fluxo e PCR real time. Para investigar os efeitos da modificação da LDE (LDE-CO), o éster de colesterololeato de colesterol (monoinsaturado), foi substituído por linoleato de colesterol (LDE-CL) (poliinsaturado) e por estearato de colesterol (LDE-CE) (saturado). Estas nanoemulsões foram submetidas a testes de estabilidade (tamanho, polidispersão, pH e peroxidação), captação celular, peroxidação lipídica celular e citotoxicidade. Nos resultados, foi observado que todas as células estudadas internalizaram o colesterol livre e éster de colesterol proporcionalmente às concentrações de LDE-CO incubadas com diferença de saturação entre elas, sendo o colesterol livre mais captado que o éster de colesterol da LDE-CO por todas as células estudadas. Além disso, os monócitos (THP-1) demonstraram maior captação de LDE-CO que as demais células. No estudo de competição com a LDL natural ocorreu uma diminuição da captação (r2-0,73), sugerindo que as duas partículas competem pelo mesmo receptor. A LDE-CO foi capaz de inibir a expressão protéica dos receptores LDL em HUVEC (3,98 vezes), monócito (6,25 vezes) e fibroblasto (3,70 vezes) e a expressão gênica em monócito e HUVEC. Por citometria de fluxo, a expressão protéica do LDL-r em H292 e fibroblasto diminuiu. Em HUVEC a LDE-CO aumentou a expressão protéica em 3,57 vezes, já em monócito, a LDE-CO diminuiu a expressão gênica e protéica (3,15 vezes) do LRP-1. Em macrófago e em H292, a LDE-CO aumentou a expressão gênica do LRP-1. A LDE-CO foi capaz de aumentar a expressão gênica e protéica (3,1 vezes) do CD36 em HUVEC, diminuir a expressão protéica (4,34 vezes) em macrófago e diminuir a expressão gênica e protéica (2,94 vezes) em H292. A LDE foi capaz de aumentar a expressão protéica (2,09 vezes) do CD68 em H292, e aumentar a expressão gênica em monócito e macrófago. A linhagem celular que apresentou maior taxa de sobrevivência na presença da LDE-CO foi o fibroblasto. Nas análises dos efeitos da modificação química da LDE, a LDE-oleato apresentou o tamanho e a lipoperoxidação menores que a LDE-linoleato e LDE-estearato. Nenhuma das LDEs apresentou modificação da estabilidade antes de 30 dias. As células apresentaram maior lipoperoxidação na presença de LDECL quando comparada à presença de LDE-CO e LDE-CE. A captação de [3H]-colesterol livre foi maior que de éster de colesterol das três LDEs por todas as células estudadas. A composição da LDE com oleato de colesterol foi a que apresentou características mais favoráveis em termos de tamanho de partículas e susceptibilidade à peroxidação. A captação celular do colesterol livre foi maior do que a do éster de colesterol em todas as linhagens estudadas das três LDEs, sugerindo que o colesterol livre possa dissociar-se da LDE e ser captado pelas células por vias não específicas. Os dados obtidos neste trabalho ajudam na compreensão dos mecanismos de captação e da influência da composição na estabilidade e adequação do sistema LDE e outros similares às suas potenciais aplicações terapêuticas ou diagnósticas. / With fat composition similar to natural LDL, the LDE nanoemulsion can be used to study the metabolism of LDL. Other studies have shown that LDE is uptaken by cells by LDL-r receptors. Other receptors such as LRP-1, CD36 and CD38 may also be involved in the uptake. The objectives of this study were to investigate the uptake of LDE by endothelial and tumor cells, fibroblasts, monocytes and macrophages, to identify those receptors involved in this process and to evaluate the effects on LDE uptake by changing its chemical composition. A labeled LDE with [3H]-cholesterol and [14C]- cholesteryl ester was incubated for 4 hours with cells, after which LDE uptake and competition tests were evaluated. LDL-r, LRP, CD36 and CD38 were evaluated by using immunocytochemistry methods, cytometric flow and real time PCR. To investigate the effects of LDE chemical composition modifications, cholesteryl oleate (LDE-CO) was replaced with cholesteryl linoleate (LDE-CL) and cholesterol stearate (LDE-CE). These were then tested for stability, cellular uptake, lipoperoxidation and citotoxitity. Results showed that all cells internalized [3H]-cholesterol and [14C]-cholesteryl ester proportionally to incubated LDE-CO concentrations albeit with some saturation differences. LDE-CO lipid uptake had a higher cholesterol uptake than the cholesteryl ester uptake. Furthermore, monocytes (THP-1) had a higher LDE-CO uptake than other cells. LDE-CO uptake decreased (r2 -0.73) in the presence of natural LDL, suggesting that these two particles may be competing for the same receptors. LDE-CO appeared to inhibit LDL protein receptor expression in HUVEC (3.98 times), in monocytes (6.25 times) and in fibroblasts (3.70 times), as well as the gene expression in monocytes and HUVEC. A decrease in LDL-r expression in both H292 and fibroblasts was also observed. LDE-CO increased the protein expression in HUVEC 3.75 times while in monocytes, it was able to decrease gene and protein expression of LRP-1, 3.15 times. In macrophages and H292, there was an increase in genetic expression of LRP-1. LDE-CO increased the CD36 in HUVEC gene and protein expressions 3.1 times, decreased the macrophage protein expression 4.34 times and decreased the H292 gene and protein expression 2.94 times. LDE increased protein expression 2.09 times in CD68 in H292 and increase gene expression in both monocytes and macrophages. Fibroblasts presented the highest survival rate in the presence of LDE-CO of all cells studied. The LDE chemical modification effect studies, presented smaller sized LDE-CO and less lipoperoxidation than LDE-CL and LDE-CE presented no stability modifications in less than 30 days. Cells presented higher lipoperoxidation in the presence of LDE-CL when compared to the presence of LDE-CO and LDE-CE. [3H]-cholesterol was greater than cholesteryl ester for all three LDE types in all the studied cells. LDE-CO presented favorable characteristics in terms of particle size and susceptibility to peroxidation. Cholesterol cell uptake was higher than that of cholesteryl ester for all LDEs of all the studied cells which suggests that that cholesterol may be capable of disassociating itself from LDE and being uptaken by cells through non-specific pathways. The results of this study can help to better understand the mechanisms of uptake by cells, the effects of stability and LDE system adequation for therapeutic and diagnostic applications.

Dissertation (Ph.D.) -- University of Texas Southwestern Medical Center at Dallas, 2008. / Vita. Bibliography: p. 135-148.

A nanoemulsão LDE tem composição lipídica semelhante à da LDL natural e é utilizada para estudos do metabolismo da LDL. Estudos anteriores mostraram que a LDE é captada pelas células pelo LDL-r, porém outros receptores podem estar envolvidos nesta captação, como LRP-1, CD36 e CD68. Os objetivos deste estudo foram: investigar a captação da LDE por células endoteliais, fibroblastos, monócitos, macrófagos e H292, identificar os receptores envolvidos na captação da LDE pelas mesmas células e avaliar os efeitos da modificação química da LDE sobre a estabilidade, captação celular, lipoperoxidação celular e citotoxicidade. A LDE marcada com [3H]-colesterol livre e [14C]-éster de colesterol foi incubada por 4 horas com as linhagens celulares. Após a incubação, foram realizados os testes de captação da LDE e competição da LDE com a LDL natural. A expressão dos receptores LDL-r, LRP, CD36 e CD68 foi avaliada pelos métodos de imunocitoquímica, citometria de fluxo e PCR real time. Para investigar os efeitos da modificação da LDE (LDE-CO), o éster de colesterololeato de colesterol (monoinsaturado), foi substituído por linoleato de colesterol (LDE-CL) (poliinsaturado) e por estearato de colesterol (LDE-CE) (saturado). Estas nanoemulsões foram submetidas a testes de estabilidade (tamanho, polidispersão, pH e peroxidação), captação celular, peroxidação lipídica celular e citotoxicidade. Nos resultados, foi observado que todas as células estudadas internalizaram o colesterol livre e éster de colesterol proporcionalmente às concentrações de LDE-CO incubadas com diferença de saturação entre elas, sendo o colesterol livre mais captado que o éster de colesterol da LDE-CO por todas as células estudadas. Além disso, os monócitos (THP-1) demonstraram maior captação de LDE-CO que as demais células. No estudo de competição com a LDL natural ocorreu uma diminuição da captação (r2-0,73), sugerindo que as duas partículas competem pelo mesmo receptor. A LDE-CO foi capaz de inibir a expressão protéica dos receptores LDL em HUVEC (3,98 vezes), monócito (6,25 vezes) e fibroblasto (3,70 vezes) e a expressão gênica em monócito e HUVEC. Por citometria de fluxo, a expressão protéica do LDL-r em H292 e fibroblasto diminuiu. Em HUVEC a LDE-CO aumentou a expressão protéica em 3,57 vezes, já em monócito, a LDE-CO diminuiu a expressão gênica e protéica (3,15 vezes) do LRP-1. Em macrófago e em H292, a LDE-CO aumentou a expressão gênica do LRP-1. A LDE-CO foi capaz de aumentar a expressão gênica e protéica (3,1 vezes) do CD36 em HUVEC, diminuir a expressão protéica (4,34 vezes) em macrófago e diminuir a expressão gênica e protéica (2,94 vezes) em H292. A LDE foi capaz de aumentar a expressão protéica (2,09 vezes) do CD68 em H292, e aumentar a expressão gênica em monócito e macrófago. A linhagem celular que apresentou maior taxa de sobrevivência na presença da LDE-CO foi o fibroblasto. Nas análises dos efeitos da modificação química da LDE, a LDE-oleato apresentou o tamanho e a lipoperoxidação menores que a LDE-linoleato e LDE-estearato. Nenhuma das LDEs apresentou modificação da estabilidade antes de 30 dias. As células apresentaram maior lipoperoxidação na presença de LDECL quando comparada à presença de LDE-CO e LDE-CE. A captação de [3H]-colesterol livre foi maior que de éster de colesterol das três LDEs por todas as células estudadas. A composição da LDE com oleato de colesterol foi a que apresentou características mais favoráveis em termos de tamanho de partículas e susceptibilidade à peroxidação. A captação celular do colesterol livre foi maior do que a do éster de colesterol em todas as linhagens estudadas das três LDEs, sugerindo que o colesterol livre possa dissociar-se da LDE e ser captado pelas células por vias não específicas. Os dados obtidos neste trabalho ajudam na compreensão dos mecanismos de captação e da influência da composição na estabilidade e adequação do sistema LDE e outros similares às suas potenciais aplicações terapêuticas ou diagnósticas. / With fat composition similar to natural LDL, the LDE nanoemulsion can be used to study the metabolism of LDL. Other studies have shown that LDE is uptaken by cells by LDL-r receptors. Other receptors such as LRP-1, CD36 and CD38 may also be involved in the uptake. The objectives of this study were to investigate the uptake of LDE by endothelial and tumor cells, fibroblasts, monocytes and macrophages, to identify those receptors involved in this process and to evaluate the effects on LDE uptake by changing its chemical composition. A labeled LDE with [3H]-cholesterol and [14C]- cholesteryl ester was incubated for 4 hours with cells, after which LDE uptake and competition tests were evaluated. LDL-r, LRP, CD36 and CD38 were evaluated by using immunocytochemistry methods, cytometric flow and real time PCR. To investigate the effects of LDE chemical composition modifications, cholesteryl oleate (LDE-CO) was replaced with cholesteryl linoleate (LDE-CL) and cholesterol stearate (LDE-CE). These were then tested for stability, cellular uptake, lipoperoxidation and citotoxitity. Results showed that all cells internalized [3H]-cholesterol and [14C]-cholesteryl ester proportionally to incubated LDE-CO concentrations albeit with some saturation differences. LDE-CO lipid uptake had a higher cholesterol uptake than the cholesteryl ester uptake. Furthermore, monocytes (THP-1) had a higher LDE-CO uptake than other cells. LDE-CO uptake decreased (r2 -0.73) in the presence of natural LDL, suggesting that these two particles may be competing for the same receptors. LDE-CO appeared to inhibit LDL protein receptor expression in HUVEC (3.98 times), in monocytes (6.25 times) and in fibroblasts (3.70 times), as well as the gene expression in monocytes and HUVEC. A decrease in LDL-r expression in both H292 and fibroblasts was also observed. LDE-CO increased the protein expression in HUVEC 3.75 times while in monocytes, it was able to decrease gene and protein expression of LRP-1, 3.15 times. In macrophages and H292, there was an increase in genetic expression of LRP-1. LDE-CO increased the CD36 in HUVEC gene and protein expressions 3.1 times, decreased the macrophage protein expression 4.34 times and decreased the H292 gene and protein expression 2.94 times. LDE increased protein expression 2.09 times in CD68 in H292 and increase gene expression in both monocytes and macrophages. Fibroblasts presented the highest survival rate in the presence of LDE-CO of all cells studied. The LDE chemical modification effect studies, presented smaller sized LDE-CO and less lipoperoxidation than LDE-CL and LDE-CE presented no stability modifications in less than 30 days. Cells presented higher lipoperoxidation in the presence of LDE-CL when compared to the presence of LDE-CO and LDE-CE. [3H]-cholesterol was greater than cholesteryl ester for all three LDE types in all the studied cells. LDE-CO presented favorable characteristics in terms of particle size and susceptibility to peroxidation. Cholesterol cell uptake was higher than that of cholesteryl ester for all LDEs of all the studied cells which suggests that that cholesterol may be capable of disassociating itself from LDE and being uptaken by cells through non-specific pathways. The results of this study can help to better understand the mechanisms of uptake by cells, the effects of stability and LDE system adequation for therapeutic and diagnostic applications.

Studies were funded by Colegio de Postgraduados, México. CONACyT, México. SRE, México. Ministère de l’Éducation du Québec, University of Montreal and an Operating Grant to B.D. Murphy from the Canadian Institutes of Health Research. / Résumé L’approvisionnement en cholestérol est un facteur limitant la stéroïdogenèse ovarienne. Pour cette raison, la majorité du cholestérol requis pour la synthèse des stéroïdes est importé de la circulation via les récepteurs des lipoprotéines de haute (HDL) et de basse densité (LDL) nommés scavenger receptor (SR-BI) et low-density lipoprotein receptor (LDLr). L’ARN messager de SR-BI est exprimé dans les ovaires de porcs durant toutes les étapes de la folliculogenèse ainsi que dans le corps jaune (CL). L’expression de la protéine SR-BI a également été détectée dans les follicules de souris lors du cycle œstral. Chez les deux espèces, l’expression est concentrée dans le cytoplasme et en périphérie des cellules du follicule. Les gonadotrophines induisent l'expression de SR-BI dans les cellules de la granulosa porcines, avec une expression cytoplasmique qui augmente durant la période périovulatoire, et avec une migration aux périphéries cellulaires durant la maturation du CL. Une conformation de 82 kDa de SR-BI est fortement exprimée dans le CL porcin, avec une conformation moins abondante de 57 kDa. Les différences entre les conformations sont attribuables à la glycosylation. La culture in vitro de follicules porcins avec des gonatrophines chorioniques humaines (hCG) a induit une hausse de régulation dépendante du temps du SR-BI de 82 kDa dans les cellules du granulosa. SR-BI et LDLr ont été exprimés réciproquement, avec LDLr étant le plus élévé dans les cellules folliculaires du granulosa et diminuant précipitamment avec la formation du CL. Pour explorer plus en détail les mécanismes d’approvisionnement en cholestérol de la stéroïdogenèse ovarienne, nous avons examiné des souris soumis à un traitement de désaccouplement de l'ovulation, et des souris portant la mutation nulle du gène Scarb1 (SR-BI-/-). Les résultats ont démontré que des ovocytes enfermés dans des structures lutéinisées expriment SR-BI. Les souris SR-BI-/ - présentaient de petits CLs, et de large follicules avec des cellules de thèque hypertrophiées et des kystes folliculaires avec des cavités remplies de sang et une diminution de 50% du niveau de progestérone dans le sérum. Les souris SR-BI-/ - traitées avec une combinaison de 20 g / g de mevinoline et 100  g / g de chloroquine ont démontré une diminution de 43% du niveau de progestérone sérique chez le type sauvage et de 30% chez les souris SR-BI-/ -. L’expression protéique de l’enzyme limitant pour la synthèse du cholestérol, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), a augmenté chez les souris SR-BI-/-. Nous avons présenté des preuves démontrant que les cellules des follicules expriment le SR-BI durant la stéroïdogenèse et que la lutéinisation augmente l’expression de SR-BI. La maturation post-transcriptionelle est caractérisée par la glycosylation. Sous des conditions normales, l’expression de LDLr est arrêtée durant la lutéinisation. Ainsi SR-BI devient le facteur principal pour l’importation du cholestérol extracellulaire. En plus, la perturbation extracellulaire du cholestérol synthétisé de novo et l’absorption par les LDLr chez les souris SR-BI-/- diminuent la fonction lutéal. L’homéostasie du cholestérol ovarien est très importante pour une lutéinisation adéquate et sa perturbation mène à une réduction, mais non à un blocage complet, de la fonction lutéal. En conclusion, l’expression de SR-BI est un facteur important, mais non essentiel, pour maintenir l’homéostasie du cholestérol ovarien et la synthèse des stéroïdes, et la lutéinisation. Un réseau de mécanismes complémentaires et compensatoires d’approvisionnement en cholestérol agit en concert pour assurer la synthèse des stéroïdes ovariens. / Abstract Ovarian cholesterol supply is rate limiting to ovarian steroidogenesis. For this reason, the majority of cholesterol required for steroid synthesis is imported via scavenger receptor-BI (SR-BI) and the low-density lipoprotein (LDL) receptor from circulating HDL and LDL. SR-BI mRNA is expressed in pig ovaries at all stages of folliculogenesis and in the corpus luteum (CL). SR-BI protein expression in mouse ovary during estrous cycle was also detected. In both species, expression is concentrated in cytoplasm and periphery of follicular cells. Gonadotropins induce SR-BI expression in pig granulosa cells, with cytoplasmic expression increasing through the periovulatory period, with migration to the cell periphery as the CL matured. An 82-kDa form of SR-BI is strongly expressed in the pig CL, with the less abundant 57-kDa form, differences between forms are attributable to glycosylation. In vitro culture of pig follicles with human chorionic gonadotropin (hCG) induced time-dependent upregulation of 82-kDa SR-BI in granulosa cells. SR-BI and LDL receptor were reciprocally expressed, with the latter highest in follicular granulosa cells, declining precipitously with CL formation. To further explore mechanisms of cholesterol supply to ovarian steroidogenesis, we examined mice treated to uncouple ovulation and mice bearing null mutation of the Scarb1 gene (SR-BI-/-). Results show entrapped oocytes in luteinized structures expressed SR-BI. SR-BI-/- mice displayed small corpora lutea, large follicles with theca cells hypertrophied, follicular cysts with blood filled cavities and 50% decreased in plasma progesterone. In SR-BI-/- mice, treatment with a combination of 20 g/g of mevinolin and 100 g/g of chloroquine (CHLORO) was employed to disturbed cholesterol sources. Serum progesterone was reduced by 43% in wild type and 30% in SR-BI-/- mice. The protein expression of the rate-limiting enzyme for cholesterol synthesis, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR) increased in SR-BI-/- mice. It was concluded that follicular cells express SR-BI during follicle development and luteinization causes upregulation of SR-BI expression. Posttranslational maturation is characterized by glycosylation. Under normal conditions expression of the LDLr (low density lipoprotein recepors) is extinguished during luteinization such that SR-BI becomes the principal means of importation of extracellular cholesterol. Further, perturbation of cholesterol de novo synthesis and uptake from LDLr in SR-BI-/- mice leads to a reduction of luteal function. Ovarian cholesterol homeostasis is central to adequate luteinization, and its perturbation leads to reduction, but not to complete impairment, of luteal function. We conclude that SR-BI expression is an important but not essential factor in maintaining ovarian cholesterol homeostasis, steroid synthesis and luteinization. A network of complementary and compensatory cholesterol supply mechanisms act in concert to assure ovarian steroid synthesis.

Résumé L’approvisionnement en cholestérol est un facteur limitant la stéroïdogenèse ovarienne. Pour cette raison, la majorité du cholestérol requis pour la synthèse des stéroïdes est importé de la circulation via les récepteurs des lipoprotéines de haute (HDL) et de basse densité (LDL) nommés scavenger receptor (SR-BI) et low-density lipoprotein receptor (LDLr). L’ARN messager de SR-BI est exprimé dans les ovaires de porcs durant toutes les étapes de la folliculogenèse ainsi que dans le corps jaune (CL). L’expression de la protéine SR-BI a également été détectée dans les follicules de souris lors du cycle œstral. Chez les deux espèces, l’expression est concentrée dans le cytoplasme et en périphérie des cellules du follicule. Les gonadotrophines induisent l'expression de SR-BI dans les cellules de la granulosa porcines, avec une expression cytoplasmique qui augmente durant la période périovulatoire, et avec une migration aux périphéries cellulaires durant la maturation du CL. Une conformation de 82 kDa de SR-BI est fortement exprimée dans le CL porcin, avec une conformation moins abondante de 57 kDa. Les différences entre les conformations sont attribuables à la glycosylation. La culture in vitro de follicules porcins avec des gonatrophines chorioniques humaines (hCG) a induit une hausse de régulation dépendante du temps du SR-BI de 82 kDa dans les cellules du granulosa. SR-BI et LDLr ont été exprimés réciproquement, avec LDLr étant le plus élévé dans les cellules folliculaires du granulosa et diminuant précipitamment avec la formation du CL. Pour explorer plus en détail les mécanismes d’approvisionnement en cholestérol de la stéroïdogenèse ovarienne, nous avons examiné des souris soumis à un traitement de désaccouplement de l'ovulation, et des souris portant la mutation nulle du gène Scarb1 (SR-BI-/-). Les résultats ont démontré que des ovocytes enfermés dans des structures lutéinisées expriment SR-BI. Les souris SR-BI-/ - présentaient de petits CLs, et de large follicules avec des cellules de thèque hypertrophiées et des kystes folliculaires avec des cavités remplies de sang et une diminution de 50% du niveau de progestérone dans le sérum. Les souris SR-BI-/ - traitées avec une combinaison de 20 g / g de mevinoline et 100  g / g de chloroquine ont démontré une diminution de 43% du niveau de progestérone sérique chez le type sauvage et de 30% chez les souris SR-BI-/ -. L’expression protéique de l’enzyme limitant pour la synthèse du cholestérol, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), a augmenté chez les souris SR-BI-/-. Nous avons présenté des preuves démontrant que les cellules des follicules expriment le SR-BI durant la stéroïdogenèse et que la lutéinisation augmente l’expression de SR-BI. La maturation post-transcriptionelle est caractérisée par la glycosylation. Sous des conditions normales, l’expression de LDLr est arrêtée durant la lutéinisation. Ainsi SR-BI devient le facteur principal pour l’importation du cholestérol extracellulaire. En plus, la perturbation extracellulaire du cholestérol synthétisé de novo et l’absorption par les LDLr chez les souris SR-BI-/- diminuent la fonction lutéal. L’homéostasie du cholestérol ovarien est très importante pour une lutéinisation adéquate et sa perturbation mène à une réduction, mais non à un blocage complet, de la fonction lutéal. En conclusion, l’expression de SR-BI est un facteur important, mais non essentiel, pour maintenir l’homéostasie du cholestérol ovarien et la synthèse des stéroïdes, et la lutéinisation. Un réseau de mécanismes complémentaires et compensatoires d’approvisionnement en cholestérol agit en concert pour assurer la synthèse des stéroïdes ovariens. / Abstract Ovarian cholesterol supply is rate limiting to ovarian steroidogenesis. For this reason, the majority of cholesterol required for steroid synthesis is imported via scavenger receptor-BI (SR-BI) and the low-density lipoprotein (LDL) receptor from circulating HDL and LDL. SR-BI mRNA is expressed in pig ovaries at all stages of folliculogenesis and in the corpus luteum (CL). SR-BI protein expression in mouse ovary during estrous cycle was also detected. In both species, expression is concentrated in cytoplasm and periphery of follicular cells. Gonadotropins induce SR-BI expression in pig granulosa cells, with cytoplasmic expression increasing through the periovulatory period, with migration to the cell periphery as the CL matured. An 82-kDa form of SR-BI is strongly expressed in the pig CL, with the less abundant 57-kDa form, differences between forms are attributable to glycosylation. In vitro culture of pig follicles with human chorionic gonadotropin (hCG) induced time-dependent upregulation of 82-kDa SR-BI in granulosa cells. SR-BI and LDL receptor were reciprocally expressed, with the latter highest in follicular granulosa cells, declining precipitously with CL formation. To further explore mechanisms of cholesterol supply to ovarian steroidogenesis, we examined mice treated to uncouple ovulation and mice bearing null mutation of the Scarb1 gene (SR-BI-/-). Results show entrapped oocytes in luteinized structures expressed SR-BI. SR-BI-/- mice displayed small corpora lutea, large follicles with theca cells hypertrophied, follicular cysts with blood filled cavities and 50% decreased in plasma progesterone. In SR-BI-/- mice, treatment with a combination of 20 g/g of mevinolin and 100 g/g of chloroquine (CHLORO) was employed to disturbed cholesterol sources. Serum progesterone was reduced by 43% in wild type and 30% in SR-BI-/- mice. The protein expression of the rate-limiting enzyme for cholesterol synthesis, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR) increased in SR-BI-/- mice. It was concluded that follicular cells express SR-BI during follicle development and luteinization causes upregulation of SR-BI expression. Posttranslational maturation is characterized by glycosylation. Under normal conditions expression of the LDLr (low density lipoprotein recepors) is extinguished during luteinization such that SR-BI becomes the principal means of importation of extracellular cholesterol. Further, perturbation of cholesterol de novo synthesis and uptake from LDLr in SR-BI-/- mice leads to a reduction of luteal function. Ovarian cholesterol homeostasis is central to adequate luteinization, and its perturbation leads to reduction, but not to complete impairment, of luteal function. We conclude that SR-BI expression is an important but not essential factor in maintaining ovarian cholesterol homeostasis, steroid synthesis and luteinization. A network of complementary and compensatory cholesterol supply mechanisms act in concert to assure ovarian steroid synthesis. / Studies were funded by Colegio de Postgraduados, México. CONACyT, México. SRE, México. Ministère de l’Éducation du Québec, University of Montreal and an Operating Grant to B.D. Murphy from the Canadian Institutes of Health Research.

Os tumores malignos apresentam um aumento da expressão dos receptores de lipoproteínas, devido ao aceleramento da proliferação celular com consequente aumento da necessidade de lípides para a síntese das membranas celulares. Esse aumento da expressão dos receptores de LDL no câncer pode ser utilizado para concentrar fármacos de ação antineoplásica em tecido tumoral, utilizando lipoproteínas ou nanoemulsões semelhantes a lipoproteínas como veículo. No presente estudo, foram investigados os efeitos da quimioterapia convencional na expressão dos receptores de LDL e LRP-1 em 16 pacientes com carcinoma de mama estádios II ou III, não candidatas à cirurgia conservadora e com indicação de tratamento quimioterápico neoadjuvante. A expressão dos receptores LDLR e LRP-1 foi avaliada por imunoistoquimica em tecido mamário normal e em tecido neoplásico antes e depois da quimioterapia neoadjuvante. Quatro pacientes que apresentaram resposta completa à quimioterapia foram retiradas da análise da expressão de receptores por não existir tumor no fragmento cirúrgico. Em relação ao LDLR, a expressão desse receptor no tecido neoplásico foi maior em comparação ao tecido normal em 8 das 11 pacientes. Após a quimioterapia, a expressão do receptor de LDL diminuiu em 6, aumentou em 4 e não se alterou em 2 pacientes. Do mesmo modo, a expressão do receptor LRP-1 no tecido tumoral estava aumentada em relação ao tecido normal em 4 pacientes das 12 avaliadas. Em comparação com o tecido tumoral antes da quimioterapia, a expressão do receptor LRP-1 diminuiu em 6, aumentou em 4 e permaneceu inalterada em 2 pacientes após a quimioterapia. Esses dados mostram que o efeito da quimioterapia na expressão dos receptores de lipoproteínas foi heterogêneo. A redução da expressão dos receptores não foi o padrão observado, o que indica que o uso de sistemas de carreamento de fármacos via receptores de LDL para o tratamento do câncer pode ser de grande importância. Esses resultados podem contribuir para o desenho de futuros estudos clínicos / Proliferative tumor cells present a high expression of LDL receptors due to accelerated mitosis rates which takes to increased need of lipids internalization for building new membranes. Upregulation of LDL receptors may be used as a gate to deliver anticancer drugs to tumor tissues using lipoproteins or artificial nanoemulsions as vehicle. This study investigated the effects of conventional chemotherapy on the expression of LDL and LRP-1 receptors in 16 patients with breast cancer in stage II or III who were not candidates to conservative surgery and with indication of neo-adjuvant chemotherapy. Expression of LDL and LRP-1 receptor was evaluated by immunohistochemistry in normal and neoplastic breast tissue before and after chemotherapy. For absence of tumor in the surgical fragments, 4 patients who presented complete response to chemotherapy were excluded from this analysis. In relation of LDLR, the expression in neoplastic tissue was higher than in normal tissue in 8 of 11 patients. After chemotherapy, LDL receptor expression diminished in 6, increased in 4 and unchanged in 2 patients. Expression of LRP-1 in tumor tissue was higher in 4 of 12 patients when compared to normal tissue. After chemotherapy, the expression of LRP-1 diminished in 6, increased in 4 and showed no difference in 2 patients. These data show that the chemotherapy effects on the tumor expression of LDL receptors were very heterogeneous. The diminution of the receptor expression is not the post-chemotherapy pattern, allowing the use of drug carrier systems that target cancer cells via the LDL receptor pathway. These results may contribute for the design of future clinical assays

Os tumores malignos apresentam um aumento da expressão dos receptores de lipoproteínas, devido ao aceleramento da proliferação celular com consequente aumento da necessidade de lípides para a síntese das membranas celulares. Esse aumento da expressão dos receptores de LDL no câncer pode ser utilizado para concentrar fármacos de ação antineoplásica em tecido tumoral, utilizando lipoproteínas ou nanoemulsões semelhantes a lipoproteínas como veículo. No presente estudo, foram investigados os efeitos da quimioterapia convencional na expressão dos receptores de LDL e LRP-1 em 16 pacientes com carcinoma de mama estádios II ou III, não candidatas à cirurgia conservadora e com indicação de tratamento quimioterápico neoadjuvante. A expressão dos receptores LDLR e LRP-1 foi avaliada por imunoistoquimica em tecido mamário normal e em tecido neoplásico antes e depois da quimioterapia neoadjuvante. Quatro pacientes que apresentaram resposta completa à quimioterapia foram retiradas da análise da expressão de receptores por não existir tumor no fragmento cirúrgico. Em relação ao LDLR, a expressão desse receptor no tecido neoplásico foi maior em comparação ao tecido normal em 8 das 11 pacientes. Após a quimioterapia, a expressão do receptor de LDL diminuiu em 6, aumentou em 4 e não se alterou em 2 pacientes. Do mesmo modo, a expressão do receptor LRP-1 no tecido tumoral estava aumentada em relação ao tecido normal em 4 pacientes das 12 avaliadas. Em comparação com o tecido tumoral antes da quimioterapia, a expressão do receptor LRP-1 diminuiu em 6, aumentou em 4 e permaneceu inalterada em 2 pacientes após a quimioterapia. Esses dados mostram que o efeito da quimioterapia na expressão dos receptores de lipoproteínas foi heterogêneo. A redução da expressão dos receptores não foi o padrão observado, o que indica que o uso de sistemas de carreamento de fármacos via receptores de LDL para o tratamento do câncer pode ser de grande importância. Esses resultados podem contribuir para o desenho de futuros estudos clínicos / Proliferative tumor cells present a high expression of LDL receptors due to accelerated mitosis rates which takes to increased need of lipids internalization for building new membranes. Upregulation of LDL receptors may be used as a gate to deliver anticancer drugs to tumor tissues using lipoproteins or artificial nanoemulsions as vehicle. This study investigated the effects of conventional chemotherapy on the expression of LDL and LRP-1 receptors in 16 patients with breast cancer in stage II or III who were not candidates to conservative surgery and with indication of neo-adjuvant chemotherapy. Expression of LDL and LRP-1 receptor was evaluated by immunohistochemistry in normal and neoplastic breast tissue before and after chemotherapy. For absence of tumor in the surgical fragments, 4 patients who presented complete response to chemotherapy were excluded from this analysis. In relation of LDLR, the expression in neoplastic tissue was higher than in normal tissue in 8 of 11 patients. After chemotherapy, LDL receptor expression diminished in 6, increased in 4 and unchanged in 2 patients. Expression of LRP-1 in tumor tissue was higher in 4 of 12 patients when compared to normal tissue. After chemotherapy, the expression of LRP-1 diminished in 6, increased in 4 and showed no difference in 2 patients. These data show that the chemotherapy effects on the tumor expression of LDL receptors were very heterogeneous. The diminution of the receptor expression is not the post-chemotherapy pattern, allowing the use of drug carrier systems that target cancer cells via the LDL receptor pathway. These results may contribute for the design of future clinical assays